Cytometry News and Research

RSS

Novel mRNA-lipid nanoparticle vaccine encoding four mpox virus surface proteins generates robust immune responses against orthopoxviruses

Researchers described a messenger ribonucleic acid (mRNA)-lipid nanoparticle monkeypox vaccine encoding four conserved monkeypox virus surface proteins which induced monkeypox virus-specific immunity and elicited heterologous protection when challenged with lethal vaccinia virus.

23 Dec 2022

Hybrid immunity from mRNA vaccines and breakthrough Omicron infections induces stronger immune responses against Omicron BQ.1.1

Researchers evaluated plasma samples from individuals vaccinated with a fourth booster dose of mono- or bivalent mRNA SARS-CoV-2 vaccine to evaluate the recognition and neutralization capacity against the ancestral (D614G) strain and the Omicron BQ.1.1 subvariant.

23 Dec 2022

PhoreMost and ThinkCyte collaborate to advance AI based drug discovery

PhoreMost Ltd. and ThinkCyte K.K today announced a strategic research partnership aimed at advancing modern phenotypic drug screening using artificial intelligence (AI).

From PhoreMost 16 Dec 2022

Major treatment advance revealed for adults with newly diagnosed B lineage acute lymphoblastic leukemia

Late-breaking research reveals a major treatment advance for adults with newly diagnosed B lineage acute lymphoblastic leukemia (ALL).

14 Dec 2022

Immunogenicity of SARS-CoV-2 antibody response in immune naïve children and adults

Researchers compare the contribution of antibodies against the SARS-CoV-2 receptor binding domain in vaccinated and naturally infected adults and children.

12 Dec 2022

Booster COVID-19 mRNA vaccinations marginally increase the durability of neutralizing antibody responses

Researchers investigated the immunological mechanisms behind the decreasing efficacy of COVID-19 vaccines by evaluating the durability and magnitude of neutralizing antibodies and memory B and T cell responses to booster doses of mRNA COVID-19 vaccine.

8 Dec 2022

The critical role of flow cytometry in CAR+ T-Cell trials

In this interview, Ryan Muise talks to AZoNetwork about the added value of using flow cytometry in CAR T-Cell clinical trials.

From Cerba Research 6 Dec 2022

Study provides understanding of SARS-CoV-2 pulmonary infection long-term effects at the microanatomical, cellular, and molecular level

Researchers evaluated compositional and structural pulmonary alterations in PASC tissues.

5 Dec 2022

Researchers develop a polyvalent lipid nanoparticle mRNA vaccine against Monkeypox virus

Researchers developed an mRNA technology-based vaccine candidate against the monkeypox virus and evaluated its immunogenicity in animal models.

5 Dec 2022

Study suggests persistent immune activation and long COVID correlate independently with severe COVID-19

Researchers investigated whether severe COVID-19 patients exhibited inflammation and immune activation three months after hospitalization and explored the associations among COVID-19 severity, long COVID, and immune activation.

30 Nov 2022

Broadly cross-reactive antibodies that protect from SARS-CoV-2 variants are revealed by virus coldspot-driven discovery

A recent study identified neutralizing antibodies against conserved SARS-CoV-2 epitopes.

30 Nov 2022

Pediatric acute myeloid leukemia genetic subtypes with poor outcomes show increased inflammatory cytokine signaling

Researchers used ribonucleic acid (RNA) sequence data to understand the association between inflammatory cytokines and poor outcomes of pediatric Acute Myeloid Leukemia (pAML).

29 Nov 2022

Study on the immunogenicity of monkeypox virus messenger ribonucleic acid-based vaccine candidates

In a new study, researchers developed two monkeypox (MPX) virus (MPXV) quadrivalent messenger ribonucleic acid (mRNA) vaccines, mRNA-A-lipid nanoparticle (LNP) and mRNA-B-LNP.

28 Nov 2022

Proteomic analysis identifies novel phenotypes associated with COVID-19 severity in circulating immune cells

In a recent study, researchers used proteomic analysis to identify novel immune cell phenotypes associated with severe coronavirus disease 2019 (COVID-19).

22 Nov 2022

New method for isolating Omicron subvariant and evaluating resistance to therapeutic and vaccine-elicited antibodies

Researchers demonstrated a viral amplification procedure to isolate the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants.

21 Nov 2022

SARS-CoV-2 infection and mRNA vaccination prime transcriptionally distinct CD4+ T cell memory landscapes

Researchers reported that SARS-CoV-2 infection and mRNA vaccination induce distinct memory T cells.

21 Nov 2022

Study of natural killer lymphocytes transcriptionally reprogrammed by vaccinia virus

In a recent study posted to the bioRxiv* preprint server, researchers evaluated responses of natural killer (NK) lymphocytes to VACV (vaccinia virus) infections in vivo.

16 Nov 2022

SARS-CoV-2 ‘Deltacron’ variant exhibits immune-escape properties similar to Omicron BA.1

The SARS-CoV-2 Deltacron does not exhibit higher transmissibility or immune evasion than the Omicron BA.1 variant.

16 Nov 2022

Development of a potent, broadly protective vaccine against all SARS-CoV-2 variants

In a recent study published in the journal npj Vaccines, researchers in China designed, produced, and evaluated the neutralization efficacy of a recombinant coronavirus disease 2019 (COVID-19) vaccine containing four hot-spot substitution mutations based on a prefusion-stabilized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S) trimer.

15 Nov 2022

Hemagglutinin stem immunogens may hold the key for broad protection against influenza A viruses

Researchers proposed that vaccines targeting the immunosubdominant yet conserved hemagglutinin (HA) stem could trigger broadly neutralizing antibodies (bnAbs) against influenza A viruses.